CPUO | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

35 results for “CPUO”

Trials

View all 12 →

Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

284 participants · First posted Mar 2, 2022

Active, not recruiting

Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

50 participants · First posted Jul 20, 2025

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

180 participants · First posted Sep 10, 2026

Drugs

View all 15 →

CPUY-11018

CPU-45

Organizations

TSUYAMA CHUO HOSPITAL

Japan

OFUNA CHUO HOSPITAL

Japan

AIZU CHUO HOSPITAL

Japan

News

Galderma Initiates Phase II Trial of Nemolizumab for Chronic Pruritus of Unknown Origin

Attovia Therapeutics Initiates Phase 1 Trial of Novel Anti-IL-31 Therapy for Chronic Pruritus

Galderma Launches Phase II Trials of Nemolizumab for Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Page 1 of 4